Genome Editing With TALEN, CRISPR-Cas9 and CRISPR-Cas12a in Combination With AAV6 Homology Donor Restores T Cell Function for XLP

Benjamin C. Houghton1, Neelam Panchal1, Simone A. Haas2,3, Kay O. Chmielewski2,3, Markus Hildenbeutel2,3, Thomas Whittaker1, Claudio Mussolino2,3, Toni Cathomen2,3, Adrian J Thrasher1 and Claire Booth1*

1Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, United Kingdom, 2Institute for Transfusion Medicine and Gene Therapy, Medical Center – University of Freiburg, Freiburg, Germany, 3Center for Chronic Immunodeficiency, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 4Faculty of Biology, University of Freiburg, Freiburg, Germany

X-linked lymphoproliferative disease is a rare inherited immune disorder, caused by mutations or deletions in the SH2D1A gene that encodes an intracellular adapter protein SAP (Slam-associated protein). SAP is essential for mediating several key immune processes and the immune system - T cells in particular - are dysregulated in its absence. Patients present with a spectrum of clinical manifestations, including haemophagocytic lymphohistiocytosis (HLH), dysgammaglobulinemia, lymphoma and autoimmunity. Treatment options are limited, and patients rarely survive to adulthood without an allogeneic haematopoietic stem cell transplant (HSCT). However, this procedure can have poor outcomes in the mismatched donor setting or in the presence of active HLH, leaving an unmet clinical need. Autologous haematopoietic stem cell or T cell therapy may offer alternative treatment options, removing the need to find a suitable donor for HSCT and any risk of alloreactivity. SAP has a tightly controlled expression profile that a conventional lentiviral gene delivery platform may not be able to fully replicate. A gene editing approach could preserve more of the endogenous regulatory elements that govern SAP expression, potentially providing a more optimum therapy. Here, we assessed the ability of TALEN, CRISPR-Cas9 and CRISPR-Cas12a nucleases to drive targeted insertion of SAP cDNA at the first exon of the SH2D1A locus using an adeno-associated virus serotype 6 (AAV6)-based vector containing the donor template. All nuclease platforms were capable of high efficiency gene editing, which was optimised using a serum-free AAV6 transduction protocol. We show that T cells from XLP patients corrected by gene editing tools have restored physiological levels of SAP gene expression and restore SAP-dependent immune functions, indicating a new therapeutic opportunity for XLP patients.

Keywords: TALEN, CRISPR (clustered regularly interspaced short palindromic repeat)/Cas9 (CRISPR associated protein 9)-mediated genome editing, Cas12a, X-linked lymphoproliferative disease (XLP), primary immunodeficiencies, AAV6, T cell therapy, homology-directed repair
INTRODUCTION

X-linked lymphoproliferative disease (XLP) is a rare inherited immune system disorder, affecting 1–2:1,000,000 births (Booth et al., 2011). It arises due to mutations and deletions in the SH2D1A gene, which encodes an intracellular adaptor protein SLAM-associated protein (SAP) that is critical for relaying signals received at the cell surface by SLAM family receptors (Booth et al., 2011; Cannons et al., 2011). SAP is a small 128 amino acid cytoplasmic protein consisting of a single Src homology-2 (SH2) domain and a short C-terminal tail (Sayos et al., 1998). By binding to specific tyrosine-based motifs in the cytoplasmic tail of SLAM family receptors - such as SLAM, 2B4, NTB-A, Ly9 CD84 and CRACC - via an arginine residue in the SH2 domain (Cannons et al., 2011), SAP can recruit additional proteins that can activate downstream signaling cascades.

In the absence of SAP, several immune functions are affected, including reduced T cell and NK cell cytotoxicity, a lack of NKT cell development, defective CD4 T follicular helper (T_{FH}) cell help to B cells leading to abnormal humoral function, and a reduced sensitivity to restimulation-induced cell death (RICD) that contributes to unconstrained immune responses to viral infection (Ma et al., 2006). These deficits give rise to a range of clinical manifestations, including haemophagocytic lymphohistiocytosis (HLH), dysgammaglobulinemia, lymphoma and autoimmunity (Panchal et al., 2018a).

Treatment options for XLP patients are limited and the only curative therapy is a haematopoietic stem cell transplant (HSCT), however, outcomes can be poor in the mismatched donor setting, as patients are at risk of graft-vs. host disease (GvHD). An autologous gene corrective approach could fulfil an unmet clinical need for patients lacking a well-matched donor. We have previously shown that lentiviral gene addition can restore SAP protein expression and immune function when delivered to haematopoietic stem cells (HSCs) and T cells, in several in vitro and in vivo models (Rivat et al., 2013; Panchal et al., 2018b). However, SAP has a tightly controlled expression profile, limited to T_{conv}, (not T_{reg}), NK and NKT cells. Within T cell subsets, SAP expression levels are upregulated after TCR engagement (Mehrle et al., 2005) and alter with memory or effector phenotypes (Hale et al., 2013), indicating an importance of finely tuned control and giving rise to concern that uncontrolled expression of this important signaling molecule in a conventional gene therapy procedure could cause further dysregulation. Although there is no direct evidence that irregular SAP expression is pathogenic, elevated (Geng et al., 2021) or decreased (Liu et al., 2021; Yang et al., 2021) levels are seen in several diseases, and SLAM signaling pathway alterations are implicated in autoimmunity (Comte et al., 2018; Frangoul et al., 2020; Houghton et al., 2014; Qasim et al., 2017; Stadtmauer et al., 2020; Gillmore et al., 2021).

TALENs are comprised of two customisable protein DNA binding domains, each expressed as a fusion protein to a FokI endonuclease domain that upon dimerization creates a staggered DNA double stand break when the DNA binding domains are targeted to proximal loci on the DNA. Cas9 and Cas12a nucleases are guided by short RNAs that bind to their specific DNA loci via Watson-Crick base pairing. DNA cleavage is dependent on the presence of a protospacer adjacent motif (PAM) that takes the sequence NGG for Streptococcus pyogenes Cas9 (SpCas9) and TTVT for Acidaminococcus sp. Cas12a (AsCas12a). Cas9 is now the most widely used platform, creating a blunt end cut 3 nucleotides upstream of the PAM. However, Cas12a is an attractive novel editing platform, due to its creation of a 5bp overhang (downstream of PAM, from 18 nucleotides on the non-target strand, to 23 on the target strand) that may more efficiently stimulate HDR. The double strand break created by the nucleases can be harnessed to seamlessly insert therapeutic sequences by supplying a HDR template. For haematopoietic cells, delivery of this repair template via a genome of an adeno-associated virus with a serotype 6 (AAV6) capsid has shown the greatest efficiency, and capable of correcting immune dysfunctions in several primary immune deficiencies including SCID-X1, CD40L X-CGD and Wiskott Aldrich syndrome (Genovese et al., 2014; Kuo et al., 2018; Pavel-Dinu et al., 2019; Rai et al., 2020; Sweeney et al., 2021).

Most manifestations of XLP result from defects in T cell immunity. T cells offer an attractive therapeutic candidate, due to their accessibility and amenability to genome editing, and have an established safety record in many clinical trials for HIV and cancer immunotherapy (Tebas et al., 2014; Qasim et al., 2017; Panchal, et al., 2021). We have previously demonstrated that adoptive transfer of gene corrected T cells rescues a murine model of SAP deficiency alongside cellular and humoral abnormalities in XLP patient T cells (Panchal et al., 2018b). Here we set out to show proof of concept for gene editing platforms to correct T cell function using technologies which could then be transferred to HSC correction.

In order to allow treatment of the greatest number of patients, we designed a targeted integration of a SAP cDNA close to the initiation codon of the first exon. We identified TALEN, CRISPR-Cas9 and CRISPR-Cas12a nucleases, which were able to mediate high efficiency DNA cleavage in primary human T cells, with minimal off-target nuclease activity. When nuclease activity was coupled with an AAV6 HDR template, over 45% of XLP patient T cells showed targeted insertion of SAP cDNA. A serum-free transduction protocol optimised the editing procedure by reducing the AAV6 dose required. Finally, we show that gene edited XLP patient T cells have a restored, physiological level of SAP protein expression and restored SAP-dependent immune functions equal to that of healthy controls in immunooassays of T:B signaling, restimulation-induced cell death (RICD) and cytotoxicity. These data indicate that an
autologous gene editing strategy could present a highly effective therapy for XLP patients.

RESULTS

Targeting the SH2D1A Locus at High Efficiency in T Cells by TALEN, CRISPR-Cas9 and CRISPR-Cas12a

To determine the feasibility of a gene correction strategy for XLP, we firstly aimed to determine the optimal nuclease platform for creating the site-specific DNA double strand break. A TALEN pair, three S. p.Cas9 guide RNAs (gRNA) and two A.s.Cas12a crRNAs were identified targeting loci early in exon1 of the SH2D1A gene (Figure 1A). Stimulated PBMCs were nucleofected with either in vitro-transcribed TALEN mRNA, or ribonucleoprotein (RNP) complexes of Cas9 (Alt-R® S. p.Hifi Cas9 V3, IDT) or Cas12a (Alt-R® AsCas12a Ultra, IDT) protein and their respective guides, according to the timeline (Figure 1B).

All three nuclease platforms mediated efficient gene editing with TALEN and CRISPR-Cas9 nucleofection resulting in >90%, and CRISPR-Cas12a >50% knock down of SAP protein, when assessed using intracellular staining and flow cytometry (Figure 1C and Supplementary Figure S1). This data was supported by TIDE analysis detection of insertions and deletions (INDELs) created by non-homologous end-joining DNA repair of DNA double strand breaks (Figure 1D). TALEN, Cas12a-1 and Cas9-3 were selected for...
further testing due their proximity to the start codon of the SAP coding sequence.

Minimal Detection of off Target Nuclease Activity Across Nuclease Platforms
To assess on and off-target cutting at more depth, we performed targeted next-generation sequencing (NGS) at the on-target (ON) locus and the top 10 in silico predicted off-target sites (OT1-10) for TALENs, Cas12a-1 and Cas9-3 nucleases (Determined by PROGNOS and Benchling online software, respectively, see Supplementary Table S1). NGS confirmed high efficiency modification at the on-target locus across all platforms giving a modification rate of 74, 57, and 75% for TALEN, Cas12a-1 and Cas9-3 respectively (Figures 1E–G). We detected off-target activity at two intronic loci (TALEN OT2 and Cas9-3 OT1) at low frequency (0.22 and 0.29% respectively) (Figures 1E–G). TALEN OT2 is in the third intron of the TET1 (Ten-eleven translocation methylcytosine dioxygenase 1) gene while Cas9-3 OT1 occurs in the 24th intron of RPTOR (Regulatory-associated protein of mTOR). In both cases, the distance from the corresponding exon boundaries (up/downstream) are 21900/43664bp and 451/14567bp away, respectively (Supplementary Figure S2).

SH2D1A-Targeted DNA Breaks can be Harnessed for HDR-Driven Insertion of SAP cDNA
To determine if we could harness the HDR pathway to insert a corrective SAP cDNA under its native promoter, we designed a...
series of donor templates for delivery via AAV6 vector (Figure 2A). Donors were constructed into an AAV vector genome using Gibson assembly, to maintain the transition from promoter regions into a codon optimised SAP cDNA without restriction enzyme sequences. To allow for simplified identification of positively recombined clones, a GFP reporter gene was included, either as a separate expression cassette (G7b, G14), or co-expressed with SAP and cleaved during translation via a P2A self-cleaving peptide (G15, G16). In addition, we wanted to compare the endogenous SH2D1A 3 untranslated region (UTR) to a woodchuck post-transcriptional element (WPRE). We therefore cloned either the full annotated UTR (1764bp, G16) or a shorter 745bp fragment that contains all the validated microRNA binding sites for the SAP3′UTR, and fills the AAV packaging capacity of the two-cassette format (G14) (Figure 2A). A GFP-only donor was constructed as a negative control, alongside giving the option to create a functional knockout of SAP in healthy control cells, which could provide an additional in vitro model (G7bc).

Donor constructs were tested by transducing stimulated XLP patient-derived T cells 15 min post-electroporation of TALEN mRNA (1 × 10^5 GC/cell). HDR efficiency was assessed by measuring the levels of GFP and SAP protein expression at day 5 post procedure. All donors were able to mediate HDR efficiently, as observed by GFP expression in approximately 50% of the cells, analysed by flow cytometry (Figure 2B). Intracellular SAP protein staining also analysed by flow cytometry showed that G15 and G16 were able to restore SAP protein expression at the same efficiency indicated by GFP fluorescence, as anticipated from the co-translational design. However, HDR donors containing the separate GFP expression cassette (G7b/G14) were not able to restore SAP protein expression, potentially due to suppression of the SH2D1A promoter arising from the downstream EFS promoter (Villémere et al., 2001) (Figure 2B, Supplementary Figure S3).

To confirm this result, we performed further experiments in T cells from several healthy controls using the G7bc and G15 and G16 donors. Flow cytometry analysis confirmed high efficiency editing rates of 52, 50 and 18% respectively in CD3+ T cells (Figure 2C, Supplementary Figure S4A). T cell phenotype was further interrogated using flow cytometry markers CD4, CD8, CD45RA and CD62L. Importantly for an XLP therapeutic, the purity of cells selected using FACS-sorting (Figure 2F, Supplementary Figure S5).

To assess the degree to which HDR donors can replicate endogenous levels of SAP expression, we sorted GFP + cells from the bulk population and performed SAP staining. We found there was no significant difference in the level of SAP expression betweenuntouched controls and cells that had been edited with either G15 or G16 HDR donor (Figure 2H). As expected, cells that had been edited with the G7bc donor and FACS-sorted had a complete knockout of SAP protein (Figure 2G, Supplementary Figure S6). From these data we concluded that the higher rates of editing achieved with the G15 donor, coupled with a highly favourable expression profile merited its use for all further experiments. To confirm that the SAP-containing donors were integrating at the correct loci we performed an in/out PCR, using a forward primer that binds upstream of the 5′ limit of the left homology arm and a reverse primer binding within the codon optimized SAP cDNA. As expected, a 953bp band was evident in cells treated with TALEN and G15 or G16 donors (Supplementary Figure S4B). We also performed ddPCR on the same amplicon, obtaining copy numbers (relative to an albumin control amplicon of similar length) consistent with the purity of cells selected using FACS-sorting (Supplementary Table S2).
We achieved an average of 45 and 46% gene corrected lymphocytes, as indicated by GFP fluorescence and intracellular SAP staining respectively (Figure 4A, Supplementary Figure S9). Crucially, levels of SAP protein expression were highly similar to that of healthy controls. Furthermore, cells that had been transduced with HDR AAV but not electroporated had similar SAP protein to unedited patient cells indicating low levels of expression originating from non-integrated HDR vector (Figure 4B). Similarly to healthy T cell editing, we observed an equal distribution between CD4 and CD8 positive T cells (Figure 4C). Memory phenotyping markers within CD4 and CD8 T cell subsets were more varied in these samples, however, they remained broadly consistent between patient and healthy control groups throughout the experiment, and edited samples expanded to a similar extent as healthy and unedited patient cells (Figures 4D,E, Supplementary Figure S10). With this promising data we moved to test SAP-dependent immune function in three in vitro models.

**Gene Correction Restores SAP-dependent Immune Functions to XLP Patient T Cells**

It has been shown that XLP T cells have reduced sensitivity to RICD, a process that in healthy individuals constrains immune responses by triggering apoptosis in cells restimulated through the TCR (Ruffo et al., 2016; Panchal et al., 2018b). To determine if gene edited cells can regain sensitivity to RICD, we cultured the gene edited T cells for 10 days, then restimulated with a range of concentrations of OKT3 antibody for 24 h before quantification of cell death using PI viability dye in flow cytometry following an established protocol (Katz and Snow, 2013). RICD in the bulk population was restored to approximately 50% that of healthy controls, matching the rate of HDR in the bulk population. When the analysis was performed only on corrected cells (GFP+), the amount of cell death equaled that of healthy controls, indicating sensitivity to RICD has been fully restored in the gene edited cells (Figure 4F, Supplementary Figure S11).

An absence of SAP in T\(_{FH}\) cells leads to humoral deficiencies, due to insufficient levels of T:B cell signaling in germinal centres. It has been shown that this interaction can be modelled *in vitro* by culturing naïve T cells with naïve B cells in the presence of SEB for 10 days before assessing levels of cytokine and immunoglobulin in the culture supernatant by ELISA (Ma et al., 2015; Panchal et al., 2018b). Naïve XLP patient T cells that had undergone a gene editing procedure showed restored T:B cell signaling, with B cell secretion of IgG and IgM corrected to the level of healthy controls, and significantly improved T\(_{FH}\) IL-21 secretion, compared to untreated patient cells (Figures 4G–I).

XLP patient T cells exhibit defective cytotoxicity against Epstein-Barr virus (EBV)-infected B cells (Sharifi et al., 2004; Dupré et al., 2005), which can contribute to the development of HLH. To test if gene editing could restore this function, we generated EBV-specific cytotoxic T lymphocytes (CTLs), by stimulating PBMC with irradiated LCL (Lymphoblastoid cell line, generated in house using EBV-B95.8 and healthy donor PBMC). Despite restimulated T cells showing significant loss of viability during the editing process, we were able to show in one patient sample that, even at low effector:target cell ratio, gene edited XLP patient T cells had similar killing activity to healthy control cells when challenged in a chromium\(_{51}\)-release cytotoxicity assay (Figure 4J). To support this data, CTLs generated from healthy controls and edited with either G15 or G15b AAV showed similar killing activity.
G7bc HDR donors were GFP-sorted and similarly challenged. In two separate experiments, CTLs edited with SAP containing donor G15 showed equal killing to unedited healthy control CTLs, while those edited to create a SAP knockout using donor G7bc (Figure 2G) showed reduced killing activity (Figures 4J,L).
DISCUSSION

HSC gene therapy is widely used to treat primary immunodeficiencies, including XLP. However, GvHD remains a significant risk in the mismatched donor setting, leaving an unmet need that could be fulfilled by an autologous gene correction approach. We have previously shown that lentiviral vectors can be used to deliver a corrective copy of SAP cDNA into HSCs and T cells, to restore immune function in vitro and in vivo models of XLP. However, SAP has a tightly restricted profile that is challenging to replicate using this technology, which may be of particular importance when developing an HSC gene therapy approach. In this study, we aimed to use gene editing technology to create a site-specific insertion of SAP cDNA, hypothesising that this would harness more of the endogenous DNA regulatory mechanisms that govern SAP expression, to provide more physiological expression pattern and therefore a more optimal therapy in both the HSC and T cell setting.

Genome editing is centered on the creation of a site-specific DNA break, and there has been significant improvement in the specificity and efficiency of nucleases in recent years that has brought this technology into the clinic (Qasim et al., 2017; Frangoul et al., 2020). We opted to test three nuclease technologies, TALEN, CRISPR-Cas9, and AsCas12a Ultra (Zhang et al., 2021) to determine an optimal editor for the SH2D1A locus. We found all platforms capable of creating double strand DNA breaks at the SH2D1A locus at high efficiency. Cas9 creates a blunt cut, while TALENs and AsCas12a create staggered cuts that may more efficiently stimulate HDR (Zetsche et al., 2015). Despite generating INDELs at roughly half that of the Cas9 RNPs, our AsCas12a RNPs were able to mediate similar levels of HDR as Cas9. In addition, TALENs created similar INDELs to Cas9 but were able to mediate more HDR, supporting this hypothesis.

We used targeted NGS to investigate on and off-target nuclease activity at sites predicted by in silico prediction software. On target amplicons confirmed the highly efficient genome modification mediated by all three nuclease platforms. Modifications at off-target loci occurred at low frequency, and were not detected in exons, indeed the nearest exon boundary was over 450bp away for Cas9-3 OT1 (RPTOR) and over 20 kb for TALEN OT2 (TET1), suggesting the risk of mutagenesis in coding regions remains low. However, it may be possible to mitigate the TALEN off target activity by using a recently described FokI mutant (Miller et al., 2019). Miller and others identified several single residue substitutions in FokI that exhibited a significant reduction in off-target activity, up to 1000-fold in some case. The substitutions lead to a reduction in catalytic rate, allowing dissociation from mismatched targets before cleavage occurs. Although several variants may need to be tested for each locus, this technology could be readily transferred to the TALEN platform (Miller et al., 2019).

It has previously been shown that using a RNP delivery format and a high-fidelity Cas9 variant can reduce off target cutting activity of Cas9, yet, despite adopting these technologies, we found evidence of low level off-target cutting at the Cas9-3 OT1 site. Mitigation may be possible through introducing internal 2′-O-methyl-3′-phosphonooacetate modifications to gRNA, however, in the absence of established design principles, optimal modifications must be determined empirically for each guide (Ryan et al., 2018; Vakulskas and Behlke, 2019). Further Cas9 protein engineering is likely to identify additional variants with improved target specificity. Indeed, a recent study used kinetics-guided cryo-electron microscopy to identify a kinked duplex structure, formed between DNA and gRNA with mismatches only at the PAM-distal positions 18–20, that supports an active Cas9 configuration (Braivo et al., 2022). A targeted mutation (creating SuperFi-Cas9) was able ablate this structure and reduce off target activity of sgRNA with PAM-distal mismatches. Although at an early stage, these studies could be particularly useful to our application, as Cas9-3 OT1 mismatches occur at gRNA positions 19 and 20.

As both TET1 and RPTOR are important for hematopoiesis and T-cell differentiation and function, there is a possibility of mutation of intronic regulatory signals, further studies of mutations at these OT loci may be required, alongside unbiased genome-wide screening for additional loci not predicted in silico, prior to translation to the clinic (Ko et al., 2015; Wang et al., 2016). Little is known about mechanisms involved in SAP gene expression. Consensus binding site for Ets-1 and Ets-2 have been identified as being important for core promoter activity (Okamoto et al., 2004), and we have previously attempted to generate lentiviral vectors incorporating this motif by cloning proximal sections of the promoter. The expression output of these vectors was significantly below physiological levels, indicating that other motifs must be important (Panchal et al., 2018b). Our exon1 gene editing approach allows for all the upstream promoter regulatory mechanisms to be preserved. At the 3′end of SH2D1A encoding mRNA, RNA binding protein sites have been identified that could have a role in regulating SH2D1A RNA stability in the cells (Okamoto et al., 2004). In addition, several studies have validated microRNA binding sites in the SAP3′UTR that have a role in regulation of SAP (Ding et al., 2012), most prominently miRNA-31 (Heide et al., 2016; Ripamonti et al., 2017), which is known to play a role in regulating IL-2 secretion (Fan et al., 2012) and IFN signalling in CD8 T cells (Moffett et al., 2017). To take advantage of these regulatory motifs, we generated an HDR donor that incorporated the full length 3′UTR, as this strategy has been shown to improve the expression profile in other T cell editing studies (Hubbard et al., 2016). However, we did not see any notable improvement in our studies but were hampered by reduced HDR efficiency. AAV vector titre was also reduced, likely due to the full-length UTR slightly exceeding the packaging capacity of AAV particles, leading to packaging of incomplete genomes. Further studies using shorter sections of UTR, looking in different T cell populations at different time points post-activation could provide more insight into the importance of these motifs. Our construct using the woodchuck post transcriptional element (WPRE) gave rise to expression equal to that of healthy controls, and furthermore, is widely used in gene therapy vectors for primary immune deficiency (Gaspar
et al., 2006; Marangoni et al., 2009; Kohn et al., 2020), presenting a clearer path to clinical translation.

We were motivated to optimise the transduction protocols by the high cost associated with performing gene editing at clinical scale. It has been reported that AAV6 is bound and precipitated by G3BP in FBS and HS (Denard et al., 2012) leading to a reduction in transduction efficiency. Here, we show that transducing T cells in media without HS leads to significantly improved gene editing at reduced viral doses, particularly when transduction is performed prior to nucleofection. Similar findings have recently been reported where T cells are cultured using FBS, supporting this approach (Wang et al., 2015; Rogers et al., 2021). In our study, the serum-free culture period had no effect on T cell phenotype markers. This approach could offer significant savings in viral production costs needed for each clinical product. However, further optimisations may be possible, either at the level of AAV transduction—such as human serum albumin (HSA) or polyvinyl alcohol (PVA) that have increased HSC transduction (Wang et al., 2017; Yang et al., 2020), or at the level of the proteins involved in DNA repair pathway by using small molecules (Li et al., 2017; Ma et al., 2018; Bischoff et al., 2020).

In the absence of SAP, XLP patient T cells exhibit deficits in several immune functions, including reduced sensitivity to RICD, insufficient T:B cell signalling and a lack a cytotoxicity against EBV-infected B cell targets. Here, we have shown for the first time that gene editing XLP patient T cells can restore SAP-dependent immune functions to the level of healthy control cells in assays that model these deficits. Although ultimately the number of corrected T cells needed for clinical benefit can only be fully determined in clinical trial, we are guided by patients that show somatic reversion of mutations. Such patients may have a SAP replete population as low as 5–8%, which leads to significantly prolonged survival without transplant (up to 40 years reported) suggesting a significant reduction in the risk of developing HLH and possibly malignancy, even with low levels of corrected cells (Palendira et al., 2012; Hoshino et al., 2018). We have also seen in our previous work using a lentiviral strategy for T cell correction in an XLP murine model that 20–40% correction can lead to complete functional recovery (Panchal et al., 2018b). Drawing on these results, the rates of HDR reached in this work (30–50%) would be at a level that could restore a clinically relevant level of immune function in patients.

However, while a T cell product could treat several of the most severe clinical manifestations of XLP and offer a life-saving bridge to HSCT, studies have shown that NKT cells (which are absent in XLP patients) have an important role in tumour surveillance (Das et al., 2013; Weng et al., 2014), and SAP-replete NK cells can aid with clearing EBV-infected cells (Parolini et al., 2000). Here we have demonstrated across different gene editing platforms that it is possible to target the SAP gene locus with high levels of efficiency and specificity and promote corrective HDR in the context of primary T cells, leading to functional rescue. We are now transferring these technologies to HSCs with the aim of developing a gene edited HSC therapy for patients with XLP lacking a suitable donor for HSCT.

MATERIALS AND METHODS

Human Samples

Informed consent was obtained from all human subjects, including 6 unrelated XLP patients that have confirmed mutations in SH2D1A. Pt1—exon 2 deletion; Pt2—exon 2 deletion; Pt3—c.163c > t; Pt4—c.163C > T; p.Arg55X; Pt5—exon 2-4 deletion; Pt6—exon1 deletion, which was not amenable to gene editing. Pt1 was used for testing HDR donor constructs and EBV-B cell cytolysis, Pt1-5 we were used in T: B co-culture assay and analysis of MFI in corrected cells, Pt1,2,3,5 corrected cells were used for RICD assay, Pt1-6 as untreated (UT) controls.

Cell Culture

Jurkat T cells and lymphoblastoid cell lines were cultured in RPMI containing 10% Foetal bovine serum (FBS) and 1% Penicillin-streptomycin (pen-strep) and passed twice weekly using 1:10 dilution. HEK293Ts were maintained in DMEM supplemented with 10% FBS and 1% pen-strep and passed twice weekly. Cells were washed with PBS and released from the culture flask with Trypsin-EDTA (all reagents ThermoFisher Scientific) before collection and neutralisation in complete DMEM and seeding back into culture flask at a 1:10 dilution.

T Cell Stimulation and Culture

Human peripheral blood mononuclear cells (PBMC) were harvested from whole blood using Ficoll-Paque density centrifugation (GE Healthcare). PBMC were cultured in TexMACS™ Medium (Miltenyi) supplemented with 5% human serum (Sigma) and 1% pen-strep. PBMC were stimulated with Human T-Activator CD3/CD28 Dynabeads (Gibco) at 1:1 ratio, in the presence of 100 U/ml IL-2 (Proleukin) in G-Rex® 24 plates (Wilson Wolf).

TALEN mRNA Synthesis

TALEN pairs were identified and constructed as previously described (Mussolino et al., 2011). Plasmid constructs were linearised at the 3' of the expression cassette using restriction enzyme digest, then purified (Qiagen). mRNA was produced using the T7 mScript™ Standard mRNA Production System according to manufacturer’s protocol. Briefly, linearised DNA template was transcribed, treated with DNase1 and purified (RNase Mini-kit, Qiagen), before further reactions for addition of a polyA tail using the supplied enzymes, and Cap 1 structure capping. After a further purification, mRNA integrity was assessed using TapeStation (Agilent) and quantified on NanoDrop Microvolume Spectrophotometer. Left and right TALEN arms were combined at 1:1 ratio, aliquoted (7.5 µg each arm) and stored at −20°C.

CRISPR-Cas9 and CRISPR-Cas12a Design and RNP Assembly

Potential Cas9 and Cas12a target sites were identified using Benchling online software (www.benchling.com). Cas9 (Alt-R®...
S. p. HiFi Cas9 Nuclease V3, IDT) and Cas12a (Alt-R® A.s. Cas12a (Cpf1) Ultra, IDT) proteins were complexed to their respective RNA guides (Cas9 synthetic gRNA, Merck; Cas12a crRNA, IDT) at a protenguide molar ratio of 1:2.5 (Vakulskas et al., 2018) and 1:2 respectively, at room temperature for 10 min immediately prior to nucleofection.

**T Cell Editing**

T cells were cultured as described above. Dynabeads were removed using a DynaMag™-15 Magnet (Invitrogen), and cells washed in PBS and counted. For serum-free transduction prior to nucleofection, cells were washed again and resuspended in TexMACs media with pen-strep and IL-2 but without human serum. Nucleases were delivered into cells via electroporation using the Lonza 4D nucleofector, buffer P3, program EO-115 - typically 1.5-3 million cells in the 1 ml cuvette, or 0.5-1 million the 20 μl cuvette.

**Determining Nuclease Efficiency Using TIDE/ICE Analysis**

Genomic DNA was harvested from edited cells at day 5 post nucleofection (Qiagen). PCR amplicons were generated using the following primer pair for all nucleases (Fwd: TGGCCTCTGAGT AAACCGCA, Rev: AGCGAGGGATTGAGGCGAAA, product length: 718bp, Tm: 69°C) using Q5 polymerase (NEB). After PCR purification (Qiagen), amplicons were sequenced (Eurofins genomics) using the forward primer. The resulting ab.1 file was the input to the online TIDE tool (Brinkman et al., 2014) (TALEs), or ICE software (Cas9/Cas12a, Synthego) which generated the % modification score.

**Assessment of Cutting Activity at Predicted off-Target Loci**

The top 10 most highly predicted loci for off-target nuclease activity of Cas9-3 and Cas12a-1 were identified by Benchling online software, while TALEN sites were predicted using PROGNOS (http://bao.rice.edu/cgi-bin/prognos/prognos.cgi) (Fine et al., 2014). PCR amplicons were designed to generate 150-200bp with the expected cut site in the centre. DNA from male healthy donor T cells edited with each nuclease platform (alongside untreated controls) was extracted at day 3 post nucleofection (Qiagen) and used as a template for on-target and off-target PCR reactions. The amplicons were then prepared for Illumina next generation sequencing by performing end repair, adapter ligation and bar coding using the NEBNext® UltraTM II DNA Library Prep Kit (NEB) according to the manufacturer's instructions. Libraries were quantified using the ddPCR™ Library Quantification Kit for Illumina TruSeq (Biorad), before sequencing using MiSeq Reagent Kit v2, 500cycles on an Illumina MiSeq platform (Illumina). The generated paired-end reads were processed using the command line version of the CRISPResso2 pipeline (Clement et al., 2019), obtained editing frequencies were compared to the untreated control samples using a one-sided Fisher's exact test. *, **, and *** indicate p < 0.05, p < 0.01, p < 0.001, respectively.

**AAV6 Production and Purification**

An AAV2 genome plasmid was kindly provided by Professor Amit Nathwani (UCL), and the pDGM6 (RRID: Addgene_110660) AAV6 packaging plasmid by the Russel lab (University of Washington). Homology arms were amplified from healthy control genomic DNA, both right and left 850bp long in all donor constructs (Right homology arm ChrX: 124345793-124346642, left homology arm ChrX:124346644-124347493). Constructs were cloned using HiFi assembly (NEB), allowing the left homology arm sequence to run directly into a codon optimised SAP cDNA without restriction enzyme sequences. SH2D1A 3’UTR sequences were also amplified from genomic DNA, all other elements were amplified from previously described lentiviral plasmids (Rivat et al., 2013; Panchal et al., 2018b).

AAV6 particles were produced in HEK293T cells via co-transfection of pDGM6 and the HDR genome plasmid using polyethylenimine (PEI, Sigma-Aldrich) 24 h after plating in complete DMEM media (DMEM (Gibco) 10%FBS, 1% penstrep). Media was replaced after 4 h and replaced again after 24 h with 2% DMEM. After a further 48 h, the cells were released into the media by scraping, before centrifuging to separate cell pellet and culture supernatant for processing separately. AAV6 particles were precipitated from cell media using ammonium sulphate on ice for 30min before collection by centrifugation and resuspended in TD buffer (1xPBS,1mM MgCl₂, 2.5 mM KCl). The cell pellet was resuspended in TD and freeze/thaw ×4 in the presence of 0.5% deoxycholic acid (VWR), before centrifugation and harvesting the supernatant. Both fractions were incubated with benzonase 50 U/ml (Novagen) before combining prior to iodixanol-gradient centrifugation. AAV6 particles were harvested from the 40–60% gradient interface and stored at 4°C. Titration was performed using the QuickTiter™ AAV Quantitation Kit (Cell Biolabs).

**In/out PCR and ddPCR**

Primers for detection of G15 and G16 donors at the SH2D1A locus were designed using the NIH Primer-BLAST tool (Ye et al., 2012) (Fwd: TGGCACAATATGCTGAAAAGTGG; Rev: GTCTCTCTG TTGAGGCTG, amplicon length 953bp, Tm: 64°C). For ddPCR, the same primers were used with the addition of a probe CCAGGGCTTCGGAGATAGGC (5’-FAM, Internal ZEN and 3’ Iowa Black FQ, IDT). The genomic reference amplicon primers targeted albumin (Fwd GCCGTCATCTCT TGTTGGGCTG, Rev CACAAATTGAAACAGACGC ATT, amplicon length 1035bp) and probe CCTGTCATCGCC ACAAAACTCTTCC (5’HEX, Internal ZEN and 3’ Iowa Black FQ, IDT). Droplets were generated and analysed according to the manufacturer’s instructions (QX200 system, Bio-Rad). The cycling conditions were (95°C 10 min initiation, 50x (94°C 1 min, 60°C 30 s, 72°C 6 min) 98°C 10 min, store 12°C).

**Detection of SAP Protein Expression by Intracellular Staining and Flow Cytometry**

Intracellular staining of SAP was performed using the IntraPrep Permeabilization Reagent (Beckman). The primary antibody was
either mouse anti-human SH2D1A antibody (Clone 1C9 - Abnova Cat# H00004068-M01, RRID:AB_425532), or isotype control (Novus Cat# NB110-7082, RRID:AB_790752). The secondary was Goat anti-mouse polyclonal immunoglobulins RPE Goat F(ab')2 (Dako).

**T Cell Phenotyping**
The following T cell phenotyping panel was used to determine Tcm, Tem, Tscm and Tnaive populations - CD3 PE-Cy7 (Clone UCHT1), CD4 APC-Cy7 (Clone RPA-T4), CD8 APC (Clone RPA-T8), CD62L BV510 (Clone DREG-56), CD45RA BV650 (Clone HI100), CD95 BV711 (Clone DX2) (BD Biosciences).

**T:B Cell Co-Culture Assay**
PBMC were stimulated and edited as described and cultured for 7 days, before naïve T cell magnetic bead selection according to the manufacturers protocol (Miltenyi). T cells were plated at 5.0 x 10^4 cells/well in a round-bottom 96 well plate. Naïve B cells were isolated from tonsillar mononuclear cells (Miltenyi) and added to the T cells at a 1:1 ratio, in addition to 150 ng/ml staphylococcal enterotoxin B (SEB). Cells were co-cultured for 10 days, before the harvesting the supernatant for ELISA analysis of IL-21, IgG and IgM (eBioscience).

**RICD Assay**
RICD was assessed using an established protocol (Katz and Snow, 2013). Briefly, edited T cells were cultured for 10 days, before washing with PBS, counting and platting at 5.0 x 10^4 cells/well in triplicate in a 96 well plate in 100 µl media. Dilutions of OKT3 antibody (Tonbo Biosciences) were prepared at 2000 ng/ml, 200 ng/ml, and 20 ng/ml, and 100 µl added to the cells to make final concentrations of 1000 ng/ml, 100 ng/ml and 10 ng/ml in the wells.

After 24 h, PI was added (final concentration 1 µg/ml) before running a fixed volume of cell suspension from each well in flow cytometry (Cytoflex, Beckman). The data was analysed by determining the number of live cells (PI-) and comparing unstimulated controls to stimulated conditions by using the formula: % cell loss = [(1 - (# PI-restimulated cells/# PI- untreated cells)) x 100].

**Generation of EBV-B Cell Specific Cytotoxic T Lymphocytes (CTLs) and Chromium51-Release Cytotoxicity Assay**
Lymphoblastoid cell lines (LCL) were previously created from EBV-seropositive healthy donors using EBV B95.8 supernatant (Ricciardelli et al., 2014; Panchal et al., 2018b). EBV-CTLs were generated by stimulating PBMC with 40Gy-irradiated LCL, initially at 40:1 PBMC:LCL ratio in the absence of IL-2 for 10 days, then subsequently at weekly intervals at 4:1 ratio in the presence of 100 U/ml IL-2. CTLs were edited after the third stimulation and sorted by flow cytometry for corrected cells (GFP+) before a fourth restimulation. To test cytotoxic capability, LCLs were labelled with Chromium51 (Na251CrO4, Perkin Elmer) for 1 h at 37°C. An initial effector:target ratio was determined based on available effector cell numbers, then a twofold serial dilution was used to determine cytotoxic range. Labelled target cells were washed and added to the plate (5000/well) for 4 h at 37°C. 50 µl culture supernatant was taken and added to 150 µl scintillation fluid and incubated for 12 h at room temperature. C51 release was determined using a beta counter (PerkinElmer).

**Statistical Analysis**
Statistical analysis was performed with Graphpad Prism 9 software.

Data is presented as the mean ± SEM or SD as denoted in the figure legend. Statistical analysis was performed using Prism 9 software (Graphpad Software Inc.), details of statistical tests used, including all p values are indicated in the relevant figure legend.

**DATA AVAILABILITY STATEMENT**
The original contributions presented in the study are publicly available. This data can be found here: https://www.ncbi.nlm.nih.gov/sra/PRJNA799193.

**AUTHOR CONTRIBUTIONS**
BH—experiment design and execution; manuscript preparation; NP—assistance with experiments; KC/SH—NGS run and analysis; TW-ddPCR run and analysis; CM/TC—TALEN design and genome editing expertise; AT—part funder and project supervision, CB—project PI.

**FUNDING**
This work has been made possible due to funding granted by the Wellcome Trust (102769/Z/13/Z and 217112/Z/19/Z) and Action Medical Research (GN2814). In addition, this work is supported by the NIHR GOSH BRC. The views expressed are those of the authors and not necessarily those of the Wellcome Trust, AMR, the NHS, the NIHR or the Department of Health.

**ACKNOWLEDGMENTS**
We would like to thank all colleagues and collaborators - particularly Christos Georgiadis, Ulrike Mock, Ida Ricciardelli, Ayad Eddaoudi, Stuart Tangye and Yenan Bryceson - that have given time, ideas or materials to this project. We would also like to thank all XLP patients and their families, and our funders - the Wellcome Trust, Action Medical Research and the NIHR GOSH BRC. The views expressed are those of the authors and not necessarily those of the Wellcome Trust, AMR, the NHS, the NIHR or the Department of Health.

**SUPPLEMENTARY MATERIAL**
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgeed.2022.828489/full#supplementary-material
